Incidence of Rebound Hypertension after Discontinuation of Dexmedetomidine
| Autor: | James T Miller, Lauren Flieller, Melissa Pleva, Cesar Alaniz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male Time Factors Critical Care medicine.drug_class Midazolam 030106 microbiology 030204 cardiovascular system & hematology Drug Administration Schedule law.invention 03 medical and health sciences 0302 clinical medicine law medicine Humans Hypnotics and Sedatives Pharmacology (medical) Dexmedetomidine Infusions Intravenous Propofol Retrospective Studies business.industry Incidence (epidemiology) Incidence Middle Aged Intensive care unit United States Clonidine Discontinuation Intensive Care Units Outcome and Process Assessment Health Care Withholding Treatment Anesthesia Sedative Hypertension Female business medicine.drug |
| Zdroj: | PharmacotherapyReferences. 39(10) |
| ISSN: | 1875-9114 |
| Popis: | INTRODUCTION To date, no studies have evaluated the incidence of rebound hypertension occurring with the discontinuation of long-term (> 72 hrs) dexmedetomidine infusions. Rebound hypertension has been documented in the literature with clonidine, a structurally and pharmacologically similar medication. OBJECTIVES To compare the incidence of rebound hypertension associated with cessation of dexmedetomidine infusion with other sedative medications. METHODS This retrospective, matched cohort study evaluated the incidence of rebound hypertension in intensive care unit patients receiving continuous infusions of at least 72 hours in duration of dexmedetomidine, propofol, or midazolam. RESULTS The study population consisted of 216 patients: 54 treated with dexmedetomidine and 162 treated with propofol or midazolam. Rebound hypertension occurred significantly more often in patients with a history of hypertension (71.1%) than in patients with no prior hypertension (28.9%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text